Pasar al contenido principal

CARACTERIZACION DEL PAPEL DE CORTISTATINA EN LA DESREGULACION INMUNOLOGICA SUBYACENTE EN LA ISQUEMIA CEREBRAL

SAF2017-85602-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beyond wrecking a wall: revisiting the concept of blood-brain barrier breakdown in ischemic stroke

  • Castillo-González, Julia
  • González-Rey, Elena
The blood-brain barrier constitutes a dynamic and interactive boundary separating the central nervous system and the peripheral circulation. It tightly modulates the ion transport and nutrient influx, while restricting the entry of harmful factors, and selectively limiting the migration of immune cells, thereby maintaining brain homeostasis. Despite the well-established association between blood-brain barrier disruption and most neurodegenerative/neuroinflammatory diseases, much remains unknown about the factors influencing its physiology and the mechanisms underlying its breakdown. Moreover, the role of blood-brain barrier breakdown in the translational failure underlying therapies for brain disorders is just starting to be understood. This review aims to revisit this concept of "blood-brain barrier breakdown," delving into the most controversial aspects, prevalent challenges, and knowledge gaps concerning the lack of blood-brain barrier integrity. By moving beyond the oversimplistic dichotomy of an "open"/"bad" or a "closed"/"good" barrier, our objective is to provide a more comprehensive insight into blood-brain barrier dynamics, to identify novel targets and/or therapeutic approaches aimed at mitigating blood-brain barrier dysfunction. Furthermore, in this review, we advocate for considering the diverse time- and location-dependent alterations in the blood-brain barrier, which go beyond tight-junction disruption or brain endothelial cell breakdown, illustrated through the dynamics of ischemic stroke as a case study. Through this exploration, we seek to underscore the complexity of blood-brain barrier dysfunction and its implications for the pathogenesis and therapy of brain diseases., This work was supported by the grants from the Spanish Ministry of Economy and Competitiveness (SAF2017-85602-R) and the Spanish Ministry of Science and Innovation (PID2020-119638RB-I00 to EGR) and FPU-program (FPU17/02616 to JCG)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lack of cortistatin drives neuroimmune and vascular dysfunction in brain ischemia

  • Castillo-González, Julia
  • Vargas-Rodríguez, Pablo
  • Serrano-Martínez, Ignacio
  • Cuenca-Martagón, Alejandro
  • Forte-Lago, Irene
  • Price, Melanie
  • Buscemi, Lara
  • Hirt, Lorenz
  • Ruiz Rodríguez, Jose Luis
  • González-Rey, Elena
RNA-seq data are available in the GEO repository under accession number GSE302342, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302342., [Background] Ischemic stroke remains a leading cause of death and disability, with limited therapies addressing its pathophysiology. Neuroinflammation, blood–brain barrier disruption, and immune dysregulation critically contribute to both acute neuronal injury and chronic functional decline. Elucidating the endogenous factors that govern these processes and understanding the intricate interplay among them is essential for developing effective therapeutic strategies. Cortistatin, a neuropeptide expressed in the nervous and immune systems, exhibits potent immunomodulatory actions, but its role in neuroinflammatory diseases remains unclear., [Methods] In this study, we combined human and murine transcriptomic analyses with a preclinical stroke model in cortistatin-deficient mice to investigate the endogenous and therapeutic roles of cortistatin during the acute (48 h) and subacute (7 days) phases of ischemic stroke., [Results] We demonstrate for the first time that cortistatin deficiency amplified ischemia-induced transcriptional programs, heightening neuroinflammation and glial/neurovascular dysfunction, and worsening neurological outcomes. Interestingly, cortistatin deficiency accelerated aging-associated pathological features, underscoring its essential role in neuroimmune and cerebrovascular homeostasis. Conversely, cortistatin administration improved neuronal survival, mitigated immune dysfunction, and preserved myelin and vascular integrity during both the acute and subacute stages., [Conclusions] These findings provide the first evidence identifying cortistatin as an endogenous neuroimmune regulator in ischemic stroke and a promising multimodal therapeutic agent for improving acute and long-term outcomes., This work was supported by the Spanish Ministry of Economy and Competitiveness (MCIN)/Spanish Research Agency (AEI)/10.13039/501100011033 grants: SAF2017-85602-R and PID2020-119638RB-I00 (to E.G-R.), FPU-program FPU17/02616 and Ramón Areces Foundation postdoctoral fellowship (to J.C-G.), FPI-program PRE2018-084824 (to I.S-M.), PRE2021-100172 (to P.V-R.) and FPU-program FPU23/00152 (to A.C-M); the grant PROYEXCEL_00867 from the Regional Andalusian Government (to E.G.-R.); the Swiss Science Foundation FNS 310030_212233 grant to L.H, Peer reviewed